Clearsight Advises Hayden Consulting Group in its Acquisition by BGB Group

Clearsight Advisors, Inc. (“Clearsight”) is pleased to announce a successful transaction in its Healthcare and Life Sciences Services Practice. Clearsight served as the exclusive financial advisor to Hayden Consulting Group (“The Company” or “Hayden”) in its acquisition by BGB Group LLC (“BGB”), a portfolio company of Tarrant Capital IP, LLC dba TPG (“TPG”).

Hayden Consulting Group, based in Boston, MA, is a premier market and patient access consultancy renowned for resolving complex payer, reimbursement, and affordability challenges. The Company partners with leading pharma and biotech companies to deliver tailored strategies in market access management, pricing analysis and optimization, and commercialization planning—helping clients overcome barriers and improve patient access across diverse therapeutic areas. The Company’s combination of subject-matter expertise and practical execution has established Hayden as a trusted advisor to world’s top organizations navigating increasingly complex market dynamics.

Headquartered in New York City, BGB Group is a leading commercial solutions partner delivering breakthrough strategies and execution for biopharmaceutical companies. Its integrated capabilities span medical communications, advertising, strategic consulting, and market access solutions combining scientific, strategic, and creative expertise to help brand teams realize their full commercial potential.

Together with the backing of TPG, this combination unites Hayden’s proven market and patient access expertise with BGB’s scientific, strategic, and creative prowess—creating an expanded Strategic Advisory practice that delivers breakthrough commercial solutions across the entire portfolio and brand lifecycle. Clients will benefit from a fully integrated partner that helps untangle access complexity, overcome affordability challenges, navigate real-world launch dynamics, and unlock their full commercial potential.

Dave MacDougall, Co-Founder and Managing Director of Hayden, commented “This transaction was a significant milestone for Hayden, and Clearsight’s guidance made the process clear and manageable every step of the way. Their understanding of our business, combined with their targeted coverage of the pharma services landscape, enabled us to stay focused on our growth and long-term vision”.

“The strength of Hayden lies in their ability to translate complex market access challenges into clear, actionable strategies. This achievement expands their capacity to deliver meaningful commercialization solutions for clients and reinforces their leadership in an evolving healthcare landscape,” remarked Tory Steel, Clearsight Managing Director.

Clearsight Co-Founder and Managing Director, Greg Treger, added, “Hayden has created a platform that truly stands out- in terms of capabilities, client relationships, and talent. Supporting their team throughout this process was a privilege and we look forward to seeing the impact that they will continue to make across the healthcare ecosystem.”

The Clearsight deal team included Tory Steel, Greg Treger, Austin Kuhn, Jonathan Holland, Ashton Neary, Emma Ito, and Yaseen Shah.